Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study

BACKGROUND: The anti-tumor activity of nab-paclitaxel followed by epirubicin/cyclophosphamide (EC) as neoadjuvant chemotherapy (NAC) in Asian patients remain unclear, particularly in the aggressive subtype triple-negative breast cancer (TNBC). This study aimed to evaluate the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yin, Fan, Lei, Wang, Zhong-Hua, Shao, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847528/
https://www.ncbi.nlm.nih.gov/pubmed/36426808
http://dx.doi.org/10.1093/oncolo/oyac223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847528/
https://www.ncbi.nlm.nih.gov/pubmed/36426808
http://dx.doi.org/10.1093/oncolo/oyac223

Ejemplares similares